The hATTR Patients Association came forward to call for the reimbursement approval of ‘Vyndamax’

The patient group recently delivered a ‘Statement for the insurance benefit of Vyndamax' to the Ministry of Health and Welfare and the National Health Insurance Services. The move arose among patients with the reimbursement discussions being delayed on Vyndamax (Tafamidis 61mg), which is virtually the only drug approved for the treatment of ATTR-CM (ATTR amyloidosis with cardiomyopathy).

After failing to receive the essential drug designation for Vyndamzx, Pfizer, its developer, conducted a PE evaluation on its drug and applied for reimbursement again in April this year. The company hopes t